# US 2025/0152691 A1 · Immunogenic composition for paratuberculosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152691 A1
- Document ID: US20250152691A1
- Status: Published application
- Kind: A1
- Application number: 18/954,032
- Filed: 2024-11-20
- Published: 2025-05-15
- Earliest claimed: 2018-07-11
- Assignees: HAV Vaccines Limited
- Applicants: Hav Vaccines Limited
- Inventors: John HERMON-TAYLOR
- Web page: https://patentgrep.com/patent/US20250152691A1

## CPC

- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- C07K 14/35: from Mycobacteriaceae (F)
- C12N 9/1025: {Acyltransferases (2.3)}
- C12N 9/1048: {Glycosyltransferases (2.4)}
- A61K 2039/5256: {expressing foreign proteins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A vaccine comprising a polypeptide comprising an amino acid sequence of at least 9 contiguous amino acids from the N-terminal region of MAP P900, or a polynucleotide encoding said polypeptide, for use in a method of treating or preventing MAP infection or a condition or symptom associated with MAP infection in a subject.

## Claims

### Claim 1

A Mycobacterium avium subspecies paratuberculosis (MAP) vaccine comprising a polynucleotide encoding a polypeptide which comprises a fragment of MAP P900, wherein the fragment of MAP P900 has a length of up to 150 amino acids and comprises an amino acid sequence of at least 9 contiguous amino acids from the region of MAP P900 shown in SEQ ID NO: 2.

### Claim 2 (depends on 1)

The MAP vaccine of claim 1, wherein the polypeptide comprises the amino acid sequence MVINDDAQRLLSQR (SEQ ID NO: 3).

### Claim 3 (depends on 2)

The MAP vaccine of claim 2, wherein the polypeptide comprises the amino acid sequence
(SEQ ID NO: 4)
MVINDDAQRLLSQRVANDEAALLELI

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The MAP vaccine of claim 1, wherein the polypeptide comprises the amino acid sequence VTTLADGGEVTWAID (SEQ ID NO: 7).

### Claim 6 (depends on 5)

The MAP vaccine of claim 5, wherein the polypeptide comprises the amino acid sequence VTTLADGGEVTWAIDLNA (SEQ ID NO: 8).

### Claim 7 (depends on 1)

The MAP vaccine of claim 1, wherein the polypeptide comprises the amino acid sequence EVVVAQPVWAGVDAGKADHY (SEQ ID NO: 9).

### Claim 8 (depends on 7)

The MAP vaccine of claim 7, wherein the polypeptide comprises the amino acid sequence
(SEQ ID NO: 10)
MTVTEVVVAQPVWAGVDAGKADHY

### Claim 9 (depends on 1)

The MAP vaccine of claim 1, which comprises one or more polynucleotides encoding two or more polypeptides, each comprising a fragment of MAP P900, wherein the fragment of MAP P900 has a length of up to 150 amino acids and comprises an amino acid sequence of at least 9 contiguous amino acids from the region of MAP P900 shown in SEQ ID NO: 2.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The MAP vaccine of claim 1, which comprises one or more polynucleotides encoding at least two of the following polypeptides: a polypeptide comprising the amino acid sequence MVINDDAQRLLSQR (SEQ ID NO: 3), a polypeptide comprising the amino acid sequence VTTLADGGEVTWAID (SEQ ID NO: 7), and a polypeptide comprising the amino acid sequence
(SEQ ID NO: 9)
EVVVAQPVWAGVDAGKADHY

### Claim 12 (depends on 11)

The MAP vaccine of claim 11, wherein the one or more polynucleotides encode a polypeptide comprising the amino acid sequence MVINDDAQRLLSQRVANDEAALLELI (SEQ ID NO: 4), a polypeptide comprising the amino acid sequence VTTLADGGEVTWAIDLNA (SEQ ID NO: 8) and/or a polypeptide comprising the amino acid sequence MTVTEVVVAQPVWAGVDAGKADHY (SEQ ID NO: 10).

### Claim 13 (depends on 1)

The MAP vaccine of claim 1, wherein the polypeptide comprises the amino acid sequence:
(i)
(SEQ ID NO: 11)
MVINDDAQRLLSQRX2VTTLADGGEVTWAID;
(ii)
(SEQ ID NO: 12)
MVINDDAQRLLSQRX2VTTLADGGEVTWAIDLNA;
(iii)
(SEQ ID NO: 13)
MVINDDAQRLLSQRVANDEAALLELIXVTTLADGGEVTWAID;
(iii)
(SEQ ID NO: 14)
MVINDDAQRLLSQRVANDEAALLELIX2VTTLADGGEVTWAIDLNA;
(iv)
(SEQ ID NO: 15)
EVVVAQPVWAGVDAGKADHYX1MVINDDAQRLLSQR;
(vi)
(SEQ ID NO: 16)
EVVVAQPVWAGVDAGKADHYX1MVINDDAQRLLSQRVANDEAALLELI;
(vii)
(SEQ ID NO: 17)
MTVTEVVVAQPVWAGVDAGKADHYX1MVINDDAQRLLSQR;
(viii)
(SEQ ID NO: 18)
MTVTEVVVAQPVWAGVDAGKADHYX1MVINDDAQRLLSQRVANDEAALLE
LI;
(ix)
(SEQ ID NO: 52)
MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAID;
(x)
(SEQ ID NO: 146)
MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNA;
(xi)
(SEQ ID NO: 60)
MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNAGGAALLIA
LLIAAGQRLLYIPG[[X3]]ATVHHAAGSYRGE;
[[or]]
(xii)
(SEQ ID NO: 61)
MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNAGGAALLIA
LLIAAGQRLLYIPGRTVHHAAGSYRGE;
(xiii)
(SEQ ID NO: 83)
MTVTEVVVAQPVWAGVDAGKADHYCMVINDDAQRLLSQRVANDEAALLEL
IAAVTTLADGGEVTWAIDLNAGGAALLIALLIAAGQRLLYIPG[[X3]]
ATVHHAAGSYRGE;
or
(xiv)
(SEQ ID NO: 58)
MTVTEVVVAQPVWAGVDAGKADHYCMVINDDAQRLLSQRVANDEAALLEL
IAAVTTLADGGEVTWAIDLNAGGAALLIALLIAAGQRLLYIPGRTVHHAA
GSYRGE,
wherein X1 is a peptide linker or C, X2 is a peptide linker, A or AA.

### Claim 14 (depends on 13)

The MAP vaccine of claim 13, wherein the polypeptide comprises the amino acid sequence
(i)
(SEQ ID NO: 19)
EVVVAQPVWAGVDAGKADHYXIMVINDDAQRLLSQRVANDE
AALLELI X2VTTLADGGEVTWAIDLNA;
or
(ii)
(SEQ ID NO: 20)
MTVTEVVVAQPVWAGVDAGKADHYXIMVINDDAQRLLSQRV
ANDEAALLELI X2VTTLADGGEVTWAIDLNA,
wherein X1 is a peptide linker or C and X2 is a peptide linker, A or AA.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The MAP vaccine of claim 1, further comprising at least one polynucleotide encoding an additional MAP polypeptide, or a fragment thereof.

### Claim at position 17

17-18. (canceled)

### Claim 19 (depends on 17)

The MAP vaccine of claim 17, wherein the additional MAP polypeptide is at least one of the following: a ahpC polypeptide, a gsd polypeptide, a p12 polypeptide and a mpa polypeptide, wherein:
(a) said ahpC polypeptide has the amino acid sequence given in SEQ ID NO: 32; and/or
(b) said gsd polypeptide has the amino acid sequence given in SEQ ID NO: 34; and/or
(c) said pl2 polypeptide has the amino acid sequence given in SEQ ID NO: 36 or SEQ ID NO: 38; and/or
(d) said mpa polypeptide bas the amino acid sequence given in SEQ ID NO: 40.

### Claim 20 (depends on 19)

The MAP vaccine of claim 19, wherein the polypeptide comprises the amino acid sequence shown in SEQ ID NO: 41, wherein a peptide comprising the amino acid sequence MVINDDAQRLLSQR is added at the N-terminus or inserted between: positions 7 and 8, positions 199 and 200, positions 442 and 443, positions 577 and 578, and/or positions 820 and 821; or the amino acid sequence shown in SEQ ID NO: 42, wherein a peptide comprising the amino acid sequence MVINDDAQRLLSQR is added at the N-terminus or inserted between: positions 7 and 8, positions 199 and 200, positions 442 and 443, positions 582 and 583, and/or positions 825 and 826.

### Claim 21 (depends on 20)

The MAP vaccine of claim 20, wherein the polypeptide comprises the amino acid sequence shown in any one of SEQ ID NOs: 62, 63, 64, 65, 67, 68 and 69.

### Claim at position 21

22-36. (canceled)

### Claim 37 (depends on 1)

The MAP vaccine of claim 1, wherein the polynucleotide is comprised in a vector.

### Claim 38

(canceled)

### Claim 39 (depends on 37)

The MAP vaccine claim 37, wherein the vector is a viral vector.

### Claim 40 (depends on 39)

The MAP vaccine of claim 39, wherein the viral vector is an adenoviral vector or a poxvirus vector.

### Claim 41

(canceled)

### Claim 42 (depends on 1)

A method of treating or preventing MAP infection or a condition or symptom associated with MAP infection comprising administering to a subject in need thereof an effective amount of the MAP vaccine of claim 1.

### Claim 43

(canceled)
